NCT02830724 2026-04-06
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT02621021 2026-04-01
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04562129 2026-04-01
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05267626 2026-03-31
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT05155033 2026-02-17
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07288073 2026-02-13
TIL Therapy in cSCC and MCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT06204991 2025-08-24
ADP-TILIL7
Herlev Hospital
Phase 1 Recruiting
NCT07063875 2025-07-14
SILVER
St Vincent's Hospital, Sydney
Phase 1/2 Recruiting